Treatment of repetitive and/or traumatic cartilage degeneration including Degenerative Osteoarthritis(OA) without age limit.

CARTISTEM^® – allogeneic umbilical cord blood-derived mesenchymal stem cells, is used for the treatment of knee cartilage defects in patients with Osteoarthritis (with ICRS grade* IV cartilage defect) caused by degeneration or repetitive trauma.

*ICRS grade : A diagnostic criteria used for grading the severity of cartilage defect. Grade IV is the most severe stage with no visible cartilage remaining on the area of defect.

· Product :	CARTISTEM® (human Umbilical Cord Blood-derived Mesenchymal Stem Cells)
· Manufacturer :	MEDIPOST Co., Ltd.
· Indication :	Treatment of repetitive and/or traumatic cartilage degeneration including Degenerative Osteoarthritis (with ICRS grade IV cartilage defect) without age limit.
· Route of Administration & Dosage :	Surgical administration at 2.5 x 106 cells/500㎕/cm2 (size of knee cartilage defects).

Commercialization of CARTISTEM^®
CARTISTEM^® has been market-approved with Biologics License Application(BLA) for commercial sale by the Ministry of Food & Drug Safety(MFDS) in January 2012.